We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

A thorough examination of modern drugs that target particular receptors and metabolic pathways for glucose and fat metabolism is presented. Recent research has revealed innovative targets and ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Shares of Infinity Natural Resources jumped almost 11% in their NYSE debut, valuing the oil and natural gas producer at $1.3B. The listing ...

The international consulting firm Clarivate makes its bet among the novelties ready for the medicine cabinet this year: three ...

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has ...

The Affordable Insulin Now Act, as it is known ... combining the effects of GLP-1 with other treatments, such as with an analogue of the hormone amylin, to improve outcomes in type 2 diabetes.

Insulin icodec is an acylated insulin analogue that makes it bind strongly to albumin in the body and have reduced affinity for insulin receptors, effectively creating an inactive reservoir that ...

Request To Download Free Sample of This Strategic Report @ Highlighted with 41 tables and 85 figures, this 159-page report ?Asia Pacific Biopharmaceuticals Market 2023-2033 by Product Type, Testing ...

FREE TO READ] Critics say fragmented ownership, weak culture and a fixation on financial results have harmed innovation ...